Publications and Presentations

Corvus is committed to driving science and medicine and helping patients. We promptly and efficiently communicate our preclinical and clinical findings to the scientific, medical and patient communities because we believe disseminating knowledge and information is good for patients.

Our scientists and clinical trial investigators have published the following research papers in peer-reviewed journals and presented the following data at scientific congresses.

Presentations

Selective ITK Blockade Modulates T Helper Cell Function and Is Efficacious in Preclinical Models of T-cell Mediated Inflammatory Disease

Rahul D. Pawar¹, Lih-Yun Hsu¹, Dan Li¹, Poorva Ghosh¹, James T. Rosenbaum^{1, 2}, Richard A. Miller¹

¹Corvus Pharmaceuticals, Burlingame, CA, ²Legacy Devers Eye Institute, Portland, OR.

Poster presentation at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITKi Soquelitinib in Refractory T Cell Lymphoma

Ning Ding¹, Yan Xie¹, Yong Guo², Kecheng Li², Tingting DU¹, Zhenjun Li¹, Yuejiao Li¹, Jiaowu Cao¹, Dingyao Hu¹, Lih-Yun Hsu³, Richard Miller³, Jun Zhu¹ and Yuqin Song, MD¹

¹Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China; ²Angel Pharmaceuticals Co., Ltd., Jiaxing, China; ³Corvus Pharmaceuticals Inc, Burlingame, United States of America

Poster presentation at American Society of Hematology (ASH) 2023

Selective A2AR Blockade Synergizes with Immune Checkpoint Therapy by Potentiating Proinflammatory Th1 Helper Cell Responses

Dan Li, Poorva Ghosh, Lih-Yun Hsu, Richard A. Miller

Corvus Pharmaceuticals, Inc., Burlingame, California, United States

Poster presentation at the Japanese Cancer Association and American Association for Cancer Research (JCA-AACR) Precision Cancer Medicine International Conference

Itk Inhibitor induces Th1 skewing and host anti-tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patients

N. Ding¹, Y. Xie¹, J. Reneau², R. Miller³, S. Mahabhashyam³, L. Hsu³, Y. Guo⁴, K.C. Li⁴, T. Du¹, L. Mi¹, N. Lin¹, J. Cao¹, D. Hu¹, D. Wang¹, Y. Li¹, Z. Li¹, J. Zhu¹, Y. Song¹

¹Peking University Cancer Hospital, Department of Lymphoma, Beijing, China; ²The Ohio State University and Wexner Medical Center, Columbus, Ohio, United States of America; ³Corvus Pharmaceuticals Inc., Burlingame, California, United States of America; ⁴Angel Pharmaceuticals Co., Ltd., Jiaxing, China

Poster presentation at the International Conference on Malignant Lymphoma (ICML) Meeting

Selective ITK blockade induces antitumor responses and enhances efficacy to immune checkpoint inhibitors in preclinical models

Lih-Yun Hsu¹, Rahul Pawar¹, Dan Li¹, Poorva Ghosh¹, Kevin Nguyen¹, Carlene Williams¹, Yuqin Song², Ning Ding², Erik Verner³, and Richard Miller^1,3

¹Corvus Pharmaceuticals, Inc, Burlingame, CA, USA; ²Peking University Cancer Hospital & Institute, Beijing, China; ³Angel Pharmaceuticals Co., Ltd, Jiaxing, China

Poster presentation at the American Association for Cancer Research 2023, Orlando, FL

ITK Inhibition in T-cell Lymphomas

John Reneau, MD, PhD, The Ohio State University Comprehensive Cancer Center

Presentation at the 10th Whistler Global Summit on Hematologic Malignancies

Interleukin-2-Inductible T-Cell Kinase (ITK) Inhibition Prevents HIV Latency Reversal

Prerna Dabral^1,2, Li Du^1,2, Mohamed S. Bouzidi^1,2, Richard Miller³, Steven G. Deeks⁴, Satish K. Pillai^1,2

¹Vitalant Research Institute, San Francisco, CA, USA; ²Department of Laboratory Medicine, University of California, San Francisco, CA, USA; ³Corvus Pharmaceuticals, Burlingame, CA, USA; ⁴School of Medicine, University of California, San Francisco, CA, USA

Poster presentation at the 30th Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 2023, Seattle, WA.

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and is Active in Refractory T Cell Lymphomas

Poster presentation

Slide presentation

Yuqin Song¹, Ning Ding¹, Dok Hyun Yoon², John Reneau³, Ryan Wilcox⁴, Won Seog Kim⁵, Youn Kim⁶, Michael Khodadoust⁶, Tatyana Feldman⁷, Costas K Yannakou⁸, Pratyush Giri⁹, Jonathan Brammer³, Lih-Yun Hsu¹⁰, Hongwei Yuan¹⁰, Erik Verner¹¹, Suresh Mahabhashyam¹⁰, Richard Miller^10,11

¹Peking University Cancer Hospital & Institute, Beijing, China; ²Asan Medical Center, Seoul, South Korea; ³The Ohio State University and Wexner Medical Center, Columbus, OH, USA; ⁴University of Michigan, Ann Arbor, MI, USA; ⁵Samsung Medical Center, Seoul, South Korea; ⁶Stanford Cancer Institute, Stanford, CA, USA; ⁷John Theurer Cancer Center at HMH, Hackensack, NJ, USA; ⁸Epworth HealthCare, Melbourne, Victoria, Australia; ⁹Royal Adelaide Hospital, Adelaide, South Australia, Australia; ¹⁰Corvus Pharmaceuticals Inc, Burlingame, CA, USA; ¹¹Angel Pharmaceuticals Co., Ltd, Jiaxing, China

Poster Presentation at the 2022 American Society of Hematology Annual Meeting

Highly Selective Irreversible ITK Inhibitor CPI-818 Reduces Acute Graft-Versus Host Disease

S. Lindner¹, N. Lee¹, G. Armijo¹, M. Burgos Da Silva¹, P. S. Herrera¹, C. Nguyen¹, E.A. Dwomoh¹, R. Ghale¹, M. Smith², Ma. Perales³, K.A. Markey⁴, J. J. Buggy⁵, J. W. Janc⁵, M. R. M. Van Den Brink^1,3

¹Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Memorial Sloan Kettering Cancer Center, New York, NY, USA ²Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA ³ Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁴Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Fred Hutchinson Cancer Research Center, Seattle, Washington, USA ⁵Corvus Pharmaceuticals Inc., Burlingame, CA, USA

Poster presentation at the 2021 American Society of Hematology Annual Meeting

Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)

Jason J. Luke; Jaime R. Merchan, MD; Brett GM. Hughes, MD; Jeffrey A. Sosman, MD; Abhishek Tripathi, MD; Igor Puzanov, MD, MSCI; Thomas U. Marron, MD, PhD; Kristen A. Marrone, MD; Craig M. Hill, PhD; James Janc, PhD; Jenny Rudnick, BS, PhD; Shenshen Hu, PhD; Mehrdad Mobasher, MD, MPH; Suresh Mahabhashyam, MD, MPH; Richard A. Miller, MD

Poster presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

The ITK Inhibitor CPI-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and is Active in a Murine Model of ALPS

V Koneti Rao², Patrick P Ng¹, Craig M Hill¹, Richard A Miller¹, Joseph J Buggy¹, and James W Janc¹

¹Corvus Pharmaceuticals, Inc., Burlingame, CA; ²ALPS Unit, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD

Poster Presentation at the 2020 American Society of Hematology (ASH) 62nd Annual Meeting

CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Khodadoust M¹, Feldman T², Yoon DH³, Yannakou C⁴, Radeski D⁵, Kim YH⁶, Mehta-Shah N⁷, Khot A⁸, Wilcox R⁹, Kim WS¹⁰, Horwitz S¹¹, Buggy J¹², Hotson A¹², Hill C¹², Munneke B¹², Mahabhashyam S¹², Miller R¹², Janc J¹² and Mobasher M¹²

¹Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA; ²John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;³Asan Medical Center/University of Ulsan College of Medicine, Seoul, Korea, Republic of (South); ⁴Epworth HealthCare, Melbourne, Australia; ⁵Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, Australia; ⁶Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA; ⁷Division of Medical Oncology, Washington University School of Medicine, St Louis, MO;⁸Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia;⁹University of Michigan, Ann Arbor, MI; ¹⁰Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South); ¹¹Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY; ¹²Corvus Pharmaceuticals, Inc., Burlingame, CA

Poster presentation at the 2020 American Society of Hematology (ASH) 62nd Annual Meeting

Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Gerard Criner, M.D., Chair & Professor, Thoracic Medicine & Surgery, Lewis Katz School of Medicine at Temple University

Oral presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Criner G¹, Mobasher M², Hill C², Hu S², Mahabhashyam S², Brody J³, Marron T³, Willingham S², Miller R²

¹Temple University Hospital, Philadelphia, PA, USA; ²Corvus Pharmaceuticals Inc, Burlingame, CA, USA; ³Icahn School of Medicine at Mount Sinai, New York, NY, USA

Poster presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

CD68+ Tumor-Associated Myeloid Cells as the Target of Adenosine-Induced Gene Products and Predictor of Response to Adenosine Blockade with Ciforadenant (Cifo) in Renal Cell Cancer (RCC)

Voss M¹, Hotson A², Willingham S², Hughes B³, Mercan J⁴, Fong L⁵, Chu M⁶, George S⁷, Munneke B², Mobasher M², Miller R²

¹Memorial Sloan Kettering Cancer Center, New York NY, ²Corvus Pharmaceuticals, Burlingame CA, ³Royal Brisbane Hospital, Brisbane Australia, ⁴Sylvester Comprehensive Cancer Center, Miami FL, ⁵UCSF Comprehensive Cancer Center, San Francisco CA, ⁶Cross Cancer Institute, Alberta Canada, ⁷Roswell Park Cancer Institute, Buffalo NY

Poster presentation at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

Adenosine Receptor Blockade with Ciforadenant ± Atezolizumab in Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)

Fong L¹, Chu M², George S³, Hughes B⁴, Carthon B⁵, Merchan J⁶, Harshman L⁷, Munneke B⁸, Kwei L⁸, Hotson A⁸, Mobasher M⁸, Miller R⁸

¹UCSF Comprehensive Cancer Center, San Francisco CA, ²Cross Cancer Institute, Alberta Canada, ³Roswell Park Cancer Institute, Buffalo NY, ⁴Royal Brisbane Hospital, Brisbane Australia, ⁵Winship Cancer Institute, Atlanta GA, ⁶Sylvester Comprehensive Cancer Center, Miami FL, ⁷Dana-Farber Cancer Institute, Boston MA, ⁸Corvus Pharmaceuticals, Burlingame CA

Poster presentation at the American Society of Clinical Oncology 2020 Genitourinary Cancers Symposium (ASCO-GU)

CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor
Pre-clinical Characterization and Interim Results of a Phase I/Ib Dose-Escalation Trial in Patients with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD, MPH Chief Medical Officer

Oral Presentation at the 12th Annual T-Cell Lymphoma Forum in La Jolla, California, February 1, 2020

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, A Selective ITK Inhibitor that Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Corvus Senior Scientist

Poster Presentation at the American Society of Hematology (ASH) 61st Annual Meeting 2019

Immunobiology and Clinical Activity of CPI-006, an Anti-CD73 Antibody with Immunomodulating Properties in a Phase 1/1b Trial in Advanced Cancers

Jason J. Luke, M.D., FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center

Oral presentation at 2019 Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Adenosine and AMP Gene Expression Profiles Predict Response to Adenosine Pathway Therapies and Indicate a Need for Dual Blockade of CD73 and A2AR with CD73 Inhibitors

Stephen Willingham, PhD, Corvus Senior Scientist

Poster Presentation at 2019 Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Immunobiology, Preliminary Safety and Efficacy of CPI-006, an Anti-CD73 Antibody with Immune Modulating Activity, in a Phase 1 Trial in Advanced Cancers

Jason J. Luke*, John D. Powderly II, Jaime R. Merchan, Minal A. Barve, Andrew N. Hotson, Mehrdad Mobasher, Long Kwei, Gabriel Luciano, Joseph J. Buggy, Emily Piccione, Richard A. Miller

University of Chicago Comprehensive Cancer Center, Chicago, IL; Carolina BioOncology Institute, Huntersville, NC; University of Miami, Miami, FL; Mary Crowley Cancer Research Center, Dallas, TX; Corvus Pharmaceuticals Inc, Burlingame, CA

*Currently at University of Pittsburgh Medical Center

Oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Biochemical, Immunologic and In Vivo Preclinical Studies with CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor That Inhibits T-Cell Receptor Signaling, Promotes Th1 Skewing, and is Efficacious in Dogs with T-Cell Lymphomas

James W Janc^1,*, C M Hill¹, P P Ng¹, A N Hotson¹, A Madriaga¹, T P Dao-Pick¹, K S Yeung¹, E Verner1, D H Thamm², R A Miller¹ and J J Buggy¹

¹Corvus Pharmaceuticals, Burlingame CA, USA. ²Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.

Poster presentation at the 11th Annual T-cell Lymphoma Forum, La Jolla, CA, January 10-12, 2019

Interleukin-2-Inducible T-cell Kinase Inhibitors for the Treatment of T-cell Lymphoproliferative Disorders

John C. Reneau, MD, PhD¹, Steven R. Hwang, MD², Carlos A. Murga-Zamalloa, MD¹, Joseph J. Buggy, PhD³, James W. Janc, PhD³and Ryan A. Wilcox, MD, PhD¹

¹University of Michigan, Ann Arbor, MI; ²Mayo Clinic, Rochester, MN; ³Corvus Pharmaceuticals, Inc., Burlingame, CA

Poster presentation at 60th Annual ASH Meeting, San Diego, CA, Dec 1-4th 2018

CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor Has Clinical Activity in Dogs with Spontaneous T-cell Lymphoma

Douglas H. Thamm,¹ Kristen M. Weishaar,¹ Sunetra Das,¹ Antonett Madriaga,² Craig M. Hill,² Felicia M. Flicker,² Bradley H. Wolfe,² Patrick P. Ng,² Andrew N. Hotson,² Richard A. Miller,² Joseph J. Buggy,² James W. Janc²

¹Flint Animal Cancer Center, Colorado State University, Fort Collins, CO USA; ²Corvus Pharmaceuticals, Burlingame, CA USA

Poster presentation at 30th EORTC-NCI-AACR Symposium, Molecular Targets and Cancer Therapeutics, Dublin IE, Nov 13-16th 2018

Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444

Lawrence Fong, M.D., University of California, San Francisco

Oral presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Preclinical and initial Phase I clinical characterization of CPI-006: an anti-CD73 monoclonal antibody with unique immunostimulatory activity

Emily Piccione, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444

Drew Hotson, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Willingham S¹, Hotson A¹, Laport G¹, Kwei L¹, Fong L², Sznol M³, Powderly J⁴, Miller R¹

¹Corvus Pharmaceuticals, Burlingame CA, USA, ² University of California, San Francisco CA, USA, ³Yale University School of Medicine, New Haven CT, USA, ⁴Carolina BioOncology Institute, Huntersville NC, USA

Poster presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress

Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Stephen Willingham, Ph.D., Corvus Pharmaceuticals

Slide presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress

Preclinical Study of Investigational Small Molecule T-cell Signaling Pathway Inhibitor in Companion Dogs Diagnosed with T-cell Lymphoma

Ryan Wilcox, M.D., Ph.D., Assistant Professor at the University of Michigan Comprehensive Cancer Center

Oral presentation at 10th Annual T-Cell Lymphoma Forum (2018)

Clinical Activity of Adenosine A2a Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation

Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, University of Chicago Medicine

Oral presentation at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (2017)

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Lawrence Fong, M.D., Leader, Cancer Immunotherapy Program, Co-Director, Parker Institute of Cancer Immunotherapy, University of California, San Francisco

Oral presentation at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

Leisha Emens, M.D., Ph.D., Associate Professor of Oncology, John Hopkins Sidney Kimmel Comprehensive Cancer Center

Oral Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies

Stephen Willingham, Ph.D., Corvus Pharmaceuticals

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models

Po Y. Ho, Corvus Pharmaceuticals

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell function

Emily Piccione, Ph.D., Corvus Pharmaceuticals

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

Publications

The following contains links to certain websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by Corvus Pharmaceuticals, Inc. of the content of such linked websites. Corvus has no control of the content of any linked website and is not responsible for these websites or their content or availability. Corvus therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.

Soquelitinib, A Selective Inhibitor of Interleukin- 2-Inducible T Cell Kinase (ITK), is Active in Several Murine Models of T Cell-Mediated Inflammatory Disease

Lih-Yun Hsu, James T. Rosenbaum, Sarah Lindner, Yannick Allanore, Anne Cauvet, Rahul D. Pawar, Dan Li, Marcel Van Den Brink, and Richard A. Miller

bioRxiv doi: 10.1101/2023.10.27.564296

Selective Inhibition of Interleukin-2 Inducible T Cell Kinase (ITK) Enhances Anti-Tumor Immunity in Association with Th1-skewing, Cytotoxic T cell Activation, and Reduced T Cell Exhaustion

Lih-Yun Hsu, James T Rosenbaum, Erik Verner, William B Jones, Craig M. Hill, James W. Janc, Joseph J. Buggy, Ning Ding, John C. Reneau, Michael S. Khodadoust, Youn H. Kim, Ryan A. Wilcox, and Richard A. Miller

bioRxiv doi: 10.1101/2023.07.05.547822

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones, Thomas Marron, Jaime R Merchan, Brett G M Hughes, and Stephen B. Willingham

Journal for ImmunoTherapy of Cancer 2022;10:e005802. doi: 10.1136/jitc-2022-005802

Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Richard A. Miller, Pramod Guru, Philippe Bauer, Jorge Robles, Christian Tomaszewski, J. Scott Overcash, Michael Waters, Miriam Cameron,Julián Olalla Sierra, James Janc, Jenny A. Rudnick, Shenshen Hu, William B. Jones, Long Kwei, Suresh Mahabhashyam, Stephen B. Willingham, and Gerard Criner

medRxiv doi: 10.1101/2021.09.13.21263406v1

Therapeutic blockade of CXCR2 rapidly clears inflammation in arthritis and atopic dermatitis models: demonstration with surrogate and humanized antibodies

Md Jahangir Alam, Liang Xie, Caroline Ang, Farnaz Fahimi, Stephen B. Willingham, Andrew J. Kueh, Marco J. Herold, Charles R. Mackay, and Remy Robert

mAbs, 2020 12:1, DOI: 10.1080/19420862.2020.1856460

Targeting the A2AR in Cancer; Early Lessons From the Clinic

Willingham SB, Hotson AN, Miller RA

Curr. Opin. Pharmacol. 2020, 53:126–133.

Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Stephen B. Willingham, Gerard Criner, Craig Hill, Shenshen Hu, Jenny A. Rudnick, Barbara Daine-Matsuoka, Jessica Hsieh, Haider Mashhedi, Andrew N. Hotson, Joshua Brody, Thomas Marron, Emily Piccione, Joseph J. Buggy, Suresh Mahabhashyam, William B. Jones, Mehrdad Mobasher, and Richard A. Miller

medRxiv doi: 10.1101/2020.09.10.20191486

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Fong L, Hotson A, Powderly JD, et al.

Cancer Discov. 2020 10(1):40-53.

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models.

Willingham SB, Ho PY, Hotson A, et al.

Cancer Immunol Res. 2018;6(10):1136-49.

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT (adoptive cellular therapy) in murine cancer models

Leone RD, Sun I-M, Oh M-H, et al.

Cancer Immunology, Immunotherapy. 2018;67:1271-1284.